Y2 receptor agonists specifically stimulated GTPγS binding, and nanomicelles targeting the Y1 receptor prolonged the survival rate in GBM murine models, indicating that NPY-activated Y1 and Y2 receptors might participate in tumor growth [73,74]. This evidence concerns the gene NPY and glioblastoma.